PUBLICATIONS

Gynecologic Oncology 2021
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer
For more information
Viral Therapy for Glioblastoma
Glioblastoma (GBM) is the most common and aggressive brain tumor. Most patients diagnosed with GBM die of their disease within 2 years, and long-term survival is rare even after optimal surgical resection. Despite numerous efforts, very little improvement (...)
For more information
Ofranergene obadenovec
Objective. Report final results of a phase I/II study of VB-111, a targeted anti-cancer gene therapy with a dual mechanism: anti angiogenic/vascular disruption and induction of an anti-tumor directed immune response, in combination with paclitaxel in patients (...)
For more information
FOR NOZ232: In this study, upfront concomitant administration of VB-111
In this study, upfront concomitant administration of VB-111 and bevacizumab failed to improve outcomes in rGBM. Change of treatment regimen, with the lack of VB-111 monotherapy priming, may explain the differences from the favorable phase II (...)
For more information
For NOZ231: Patients with rGBM who were primed with VB-111
Patients with rGBM who were primed with VB-111 monotherapy that continued after progression with the addition of bevacizumab showed significant survival and PFS advantage, as well as specific imaging characteristics related to VB-111 (...)
For more information
Antiangiogenic virotherapy: VB-111 targeting glioma
Antiangiogenic virotherapy: VB-111 targeting glioma. Demonstrating safety and showing signs of efficacy in early phase clinical trials, VB-111 is being studied in combination with and without bevacizumab in a large phase 3 trial for recurrent glioblastoma. (...)
For more information
VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme.
VB-111: a novel anti-vascular therapeutic for glioblastoma multiforme. Glioblastoma multiforme (GBM) is among the most highly vascularized of solid tumors, contributing to the infiltrative nature of the disease, and conferring poor outcome. Due to the critical (...)
For more information
Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors.
Phase I dose-escalation study of VB-111, an antiangiogenic virotherapy, in patients with advanced solid tumors. VB-111 is an antiangiogenic agent consisting of a nonreplicating adenovirus vector (Ad-5) with a modified murine pre-proendothelin promoter leading to apoptosis of (...)
For more information
VB-111 for cancer.
VB-111 for cancer. Antibody, small molecule and protein inhibitors of angiogenesis are used in the management of several cancers. These do not specifically target tumor vascularity, and resistance can be problematic. VB-111 is a vascular-targeting agent consisting of a (...)
For more information
Antitumor Activity of VB-111, a Novel Antiangiogenic Virotherapeutic, in Thyroid Cancer Xenograft Mouse Models.
Antitumor Activity of VB-111, a Novel Antiangiogenic Virotherapeutic, in Thyroid Cancer Xenograft Mouse Models. VB-111 is an engineered antiangiogenic adenovirus that expresses Fas-c in angiogenic blood vessels and has previously been shown to have (...)
For more information
Systemic administration of radiation-potentiated anti-angiogenic gene therapy against primary and metastatic cancer based on transcriptionally controlled HSV-TK.
Systemic administration of radiation-potentiated anti-angiogenic gene therapy against primary and metastatic cancer based on transcriptionally controlled HSV-TK. Transcription-targeted gene delivery directed against angiogenic endothelial cells is a new approach against (...)
For more information
Systemic administration of a conditionally replicating adenovirus, targeted to angiogenesis, reduced lung metastases burden in cotton rats.
Systemic administration of a conditionally replicating adenovirus, targeted to angiogenesis, reduced lung metastases burden in cotton rats. Angiogenesis is an essential process for solid tumor development. To interfere with angiogenesis, AdPPE3x-E1, an adenovirus that is (...)
For more information
Antiangiogenic systemic gene therapy combined with doxorubicin administration induced caspase 8 and 9-mediated apoptosis in endothelial cells and an anti-metastasis effect
Antiangiogenic systemic gene therapy combined with doxorubicin administration induced caspase 8 and 9-mediated apoptosis in endothelial cells and an anti-metastasis effect. Ad-PPE-Fas-c is an adenovector that expresses Fas-c under the control of the modified  (...)
For more information
Specific Induction of Tumor Neovasculature Death by Modified Murine PPE-1 Promoter Armed with HSV-TK
Specific induction of tumor neovasculature death by modified murine PPE-1 promoter armed with HSV-TK. The modified PPE-1 promoter specifically induced expression in the tumor angiogenic vascular bed with a 35-fold higher expression compared to the normal vasculare bed of (...)
For more information
Transcription-controlled gene therapy against tumor angiogenesis.
Transcription-controlled gene therapy against tumor angiogenesis. A major drawback of current approaches to antiangiogenic gene therapy is the lack of tissue-specific targeting. The aim of this work was to trigger endothelial cell-specific apoptosis, using (...)
For more information
Tissue-specific gene therapy directed to tumor angiogenesis.
Tissue-specific gene therapy directed to tumor angiogenesis. Gene therapy directed specifically to the vascular wall, particularly to angiogenic endothelial cells is a prerequisite in vascular disease treatment. Angiogenesis is a major feature in many pathological conditions including wound healing, solid (...)
For more information
Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter.
Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin-1 promoter.  To develop a system for overexpressing genes in the vascular wall, we created transgenic mice using the reporter gene luciferase and the murine preproendothelin-1 promoter (...)
For more information